AIMT
Aimmune Therapeutics
AIMT
AIMT
Delisted
AIMT was delisted on the 12th of October, 2020.
125 hedge funds and large institutions have $1.07B invested in Aimmune Therapeutics in 2019 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 49 increasing their positions, 34 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
27% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 22
35% less call options, than puts
Call options by funds: $4.41M | Put options by funds: $6.83M
Holders
125
Holding in Top 10
4
Calls
$4.41M
Puts
$6.83M
Top Buyers
| 1 | +$52.8M | |
| 2 | +$14.2M | |
| 3 | +$11.4M | |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$4.98M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.12M |
Top Sellers
| 1 | -$14.7M | |
| 2 | -$9.29M | |
| 3 | -$7.78M | |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$7.7M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$5.64M |